Predictors of neonatal encephalopathy in full term infants

doi:10.1136/bmj.312.7030.580

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

More information needed about possible role of thyroxine

J Girling,
M De Swiet

Senior registrar in obstetrics and gynaecology Hammersmith Hospital, London W12 0HS
Consultant physician Queen Charlotte's and Chelsea Hospital, London W6 0XG

EDITOR,—Stuart J Adamson and colleagues suggest that maternal thyroxine treatment increases the risk of neonatal encephalopathy, with an odds ratio of between 1.2 and infinity (the mothers of six of the affected babies were taking thyroxine, compared with none of the mothers of the control babies).1 They also claim that this is biologically plausible. These statements need further qualification in view of …